P12.01 A Novel 89Zr-α-PD-1 Immuno-PET-CT May Improve Pseudoprogression Detection in a Lung Cancer Murine Model Receiving Immunotherapy

Abstract

Immune checkpoint inhibitors (ICIs) have revolutionized lung cancer treatment improving survival of non-small cell lung cancer (NSCLC) patients. Response assessment of patients on ICIs represents a challenge since an increase in tumor size or the appearance of new lesions might not reflect true disease progression (P) but pseudoprogression (PP). Pseudoprogression has been reported in a range of 3-6% in NSCLC. Conventional 18F-FDG-PET scans do not accurately discriminate P from PP. We have recently reported the efficacy of a combined blockade of PD-1 and Id1 in a lung cancer mouse model (Baraibar et al.